(22) Date of filing of Application :30/07/2023

(21) Application No.202341051234 A

(43) Publication Date: 01/09/2023

## (54) Title of the invention : NOVEL CHROMEN-3-YL-CARBAMATE DERIVATIVES AND THEIR EFFECTIVENESS AS THE INHIBITORS OF SARS-CoV-2 VIRUS 3CL PROTEASE ENZYME

(71)Name of Applicant:

1)JSS College of Pharmacy, Ooty- JSS Academy of Higher Education & Research, Mysuru

Address of Applicant: "Rocklands", Post Box No.: 20, Ooty-643001, The Nilgiris, Tamilnadu, India Nilgiris ------

Name of Applicant: NA Address of Applicant: NA (72)Name of Inventor: 1)Dr. Kalirajan Rajagopal

Address of Applicant :Associate Professor & Head, Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty-643001, The

Nilgiris, Tamilnadu Nilgiris -----

2)Mr. Kannan Raman

Address of Applicant: Research Scholar, Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty-643001, The Nilgiris, Tamilnadu Nilgiris -----

3)Dr. Srikanth Jupudi

Address of Applicant: Lecturer, Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty-643001, The Nilgiris, Tamilnadu Nilgiris -----

4)Dr. Gowramma Byran

Address of Applicant: Associate Professor, Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty-643001, The Nilgiris, Tamilnadu Nilgiris -----

5)Sankaranarayanan Murugesan

Address of Applicant :Medicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Pilani Campus, Pilani-333031. Rajasthan. India Jhunjhunu ------

(51) International classification

:A61P0031140000, C11D0003386000, A61P0031180000, A61P0031000000,

G16B0005000000

(86) International Application No

:PCT// :01/01/1900

Filing Date (87) International Publication No

: NA

(61) Patent of Addition to Application Number :NA

Filing Date

(62) Divisional to Application Number Filing Date :NA

(57) Abstract:

The present invention relates to the development of 3CL protease enzyme inhibitors, specifically the development of novel chormen-3-yl derivatives and their efficacy as inhibitors of SARS-CoV-2 virus 3CL protease enzyme. The present invention is based on Insilico, Synthesis, Characterization and aims to target B.1.1.529, Omicron Variant, and P132H mutant strains of the virus. The chromen-3-yl derivatives have shown promising results as effective inhibitors of the 3CL protease enzyme, which is crucial for the replication of the virus. The present invention provides a novel approach to combat the deadly effects of the SARS-CoV-2 virus by targeting its key enzyme through the use of chormen-3-yl derivatives. Out of the derivatives derived and obtained, K2-CoV-1, Q2-CoV-4 and K4-CoV-7 showed maximum activity against the SARS-CoV-2 virus 3CL protease enzyme.

No. of Pages: 27 No. of Claims: 7